Oral antibiotic outpatient therapy vs. placebo in the treatment of uncomplicated acute appendicitis: a randomized double-blind placebo-controlled noninferiority trialcore
APPAC IV · Horizon Europe grant · 2024-03-01–2029-02-28
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call ERC-2023-COG · scheme HORIZON-ERC · topic ERC-2023-COG. CORDIS record →
Objective
Acute appendicitis is one of the most common surgical emergencies worldwide. For over a century, surgical removal of the appendix has been considered the only treatment option. Landmark trials by our experienced APPAC team have shown that imaging confirmed uncomplicated acute appendicitis is not a surgical emergency defining antibiotics to safe and effective also with only oral antibiotics avoiding unnecessary surgeries resulting in major cost and resource savings. However, the role of antibiotics remains a major knowledge gap. Our pilot APPAC III showed that even symptomatic treatment (placebo) may be sufficient warranting a larger noninferiority trial to assess whether antibiotics are needed in the treatment of uncomplicated acute appendicitis.APPAC IV is a randomized double-blind multicenter clinical trial comparing oral moxifloxacin with placebo in an outpatient setting. APPAC IV aims to evaluate whether antibiotics and hospitalization or both can be omitted in the treatment of uncomplicated appendicitis further significantly increasing cost savings and patient satisfaction; almost 2/3 of all appendectomies (approx. 550.000 operations in Europe), the associated hospital stays, and potentially also antibiotics could be avoided.The growing global health issue of antibiotic resistance threatens effective prevention and treatment of infections. Studies on rational use of antibiotics are warranted and especially in the changing treatment paradigm of such a common disease. The translational MAPPAC II (Microbiology APPAC) substudy includes serum, rectal and fecal samples of the APPAC IV trial patients pre- and post-therapy. The effects of antibiotics on gut microbiota, gut health and correlation to serum cytokines are evaluated in this unique real-life randomized patient cohort. The development of antibiotic resistance and the underlying bacterial defence mechanisms will be evaluated in E. coli and microbiome using microbial single-cell technologies and metagenomics.
Beneficiaries (2)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| TURUN YLIOPISTO | FI | coordinator | €808,585 | |
| VARSINAIS-SUOMEN HYVINVOINTIALUE | FI | participant | €1,186,310 |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.